Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebideutorexant for MDD with Anxious Distress
NCT04080752Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of rocavorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Sep 2019; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04080752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080752.